Pharmacokinetics of melatonin in preterm infants

British Journal of Clinical Pharmacology

Volumn 76, Issue 5, 2013, Pages 725-733

  Merchant, Nazakat M ^a,b,c,d   Azzopardi, Denis V ^a,b,c,d   Hawwa, Ahmed F ^f   Mcelnay, James C ^f   Middleton, Benita ^e   Arendt, J ^e   Arichi, Tomoki ^a,b,c,d   Gressens, Pierre ^c,g   Edwards, A David ^a,b,c,d  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^d GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^e UNIVERSITY OF SURREY   (United Kingdom)

^f QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^g INSERM   (France)

Author keywords

6 sulfatoxymelatonin; Melatonin; Neuroprotective agents; Pharmacokinetics; Preterm infants

Indexed keywords

6 HYDROXYMELATONIN O SULFATE; AMOXICILLIN PLUS CLAVULANIC ACID; CAFFEINE; MELATONIN;

AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; COMPARTMENT MODEL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG HALF LIFE; FEMALE; HUMAN; INFANT; LIMIT OF DETECTION; LOADING DRUG DOSE; LOW DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; OPEN STUDY; PREMATURITY; PRIORITY JOURNAL; STEADY STATE; SUBSTITUTION THERAPY; TOTAL PARENTERAL NUTRITION; URINALYSIS;

6-SULFATOXYMELATONIN; MELATONIN; NEUROPROTECTIVE AGENTS; PHARMACOKINETICS; PRETERM INFANTS;

CIRCADIAN RHYTHM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALF-LIFE; HORMONE REPLACEMENT THERAPY; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; MALE; MELATONIN; SEX FACTORS; TISSUE DISTRIBUTION;

EID: 84877297677     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12092     Document Type: Article

References (48)

1. Wilson-Costello D, Friedman H, Minich N, Fanaroff AA, Hack M. Improved survival rates with increased neurodevelopmental disability for extremely low birth weight infants in the 1990s. Pediatrics 2005; 115: 997-1003.
2. Hintz SR, Kendrick DE, Wilson-Costello DE, Das A, Bell EF, Vohr BR, Higgins RD. Early-childhood neurodevelopmental outcomes are not improving for infants born at <25 weeks' gestational age. Pediatrics 2011; 127: 62-70.
3. Claas MJ, Bruinse HW, Koopman C, van Haastert IC, Peelen LM, de Vries LS. Two-year neurodevelopmental outcome of preterm born children
4. Volpe JJ. Cerebral white matter injury of the premature infant-more common than you think. Pediatrics 2003; 112: 176-180.
5. Doyle LW, Roberts G, Anderson PJ. Outcomes at age 2 years of infants < 28 weeks' gestational age born in Victoria in 2005. J Pediatr 2010; 156: 49-53. e1.
6. Mathiasen R, Hansen BM, Nybo Anderson AM, Greisen G. Socio-economic achievements of individuals born very preterm at the age of 27 to 29 years: a nationwide cohort study. Dev Med Child Neurol 2009; 51: 901-908.
7. Petrou S, Eddama O, Mangham L. A structured review of the recent literature on the economic consequences of preterm birth. Arch Dis Child Fetal Neonatal Ed 2011; 96: F225-232.
8. Skaper SD, Floreani M, Ceccon M, Facci L, Giusti P. Excitotoxicity, oxidative stress, and the neuroprotective potential of melatonin. Ann N Y Acad Sci 1999; 890: 107-118.
9. Welin AK, Svedin P, Lapatto R, Sultan B, Hagberg H, Gressens P, Kjellmer I, Mallard C. Melatonin reduces inflammation and cell death in white matter in the mid-gestation fetal sheep following umbilical cord occlusion. Pediatr Res 2007; 61: 153-158.
10. Husson I, Mesples B, Bac P, Vamecq J, Evrard P, Gressens P. Melatoninergic neuroprotection of the murine periventricular white matter against neonatal excitotoxic challenge. Ann Neurol 2002; 51: 82-92.
11. Olivier P, Fontaine RH, Loron G, Van Steenwinckel J, Biran V, Massonneau V, Kaindl A, Dalous J, Charriaut-Marlangue C, Aigrot MS, Pansiot J, Verney C, Gressens P, Baud O. Melatonin promotes oligodendroglial maturation of injured white matter in neonatal rats. PLoS ONE 2009; 4: e7128.
12. Reiter RJ. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr Rev 1991; 12: 151-180.
13. Guzman-Marin R, Suntsova N, Methippara M, Greiffenstein R, Szymusiak R, McGinty D. Sleep deprivation suppresses neurogenesis in the adult hippocampus of rats. Eur J Neurosci 2005; 22: 2111-2116.
14. Okatani Y, Okamoto K, Hayashi K, Wakatsuki A, Tamura S, Sagara Y. Maternal-fetal transfer of melatonin in pregnant women near term. J Pineal Res 1998; 25: 129-134.
15. Kennaway DJ, Stamp GE, Goble FC. Development of melatonin production in infants and the impact of prematurity. J Clin Endocrinol Metab 1992; 75: 367-369.
16. Jan JE, Wasdell MB, Freeman RD, Bax M. Evidence supporting the use of melatonin in short gestation infants. J Pineal Res 2007; 42: 22-27.
17. Arendt J. Melatonin and the Mammalian Pineal Gland, 1st edn. London: Chapman & Hall, 1995.
18. Bojkowski CJ, Arendt J. Factors influencing urinary 6-sulphatoxymelatonin, a major melatonin metabolite, in normal human subjects. Clin Endocrinol (Oxf) 1990; 33: 435-444.
19. Paakkonen T, Makinen TM, Leppaluoto J, Vakkuri O, Rintamaki H, Palinkas LA, Hassi J. Urinary melatonin: a noninvasive method to follow human pineal function as studied in three experimental conditions. J Pineal Res 2006; 40: 110-115.
20. Arendt J, Bojkowski C, Franey C, Wright J, Marks V. Immunoassay of 6-hydroxymelatonin sulfate in human plasma and urine: abolition of the urinary 24-hour rhythm with atenolol. J Clin Endocrinol Metab 1985; 60: 1166-1173.
21. Beal SL, Sheiner LB, Boeckmann AJ. NONMEM Users Guides. Ellicott City, MD: Icon Development Solutions, 1989; 2006.
22. Bonate PL. Pharmacokinetic-Pharmacodynamic Modeling and Simulation, 2nd edn. New York: Springer, 2006.
23. Holford NH. A size standard for pharmacokinetics. Clin Pharmacokinet 1996; 30: 329-332.
24. Meibohm B, Laer S, Panetta JC, Barrett JS. Population pharmacokinetic studies in pediatrics: issues in design and analysis. AAPS J 2005; 7: E475-487.
25. Mandema JW, Verotta D, Sheiner LB. Building population pharmacokinetic - pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm 1992; 20: 511-528.
26. Gitto E, Romeo C, Reiter RJ, Impellizzeri P, Pesce S, Basile M, Antonuccio P, Trimarchi G, Gentile C, Barberi I, Zuccarello B. Melatonin reduces oxidative stress in surgical neonates. J Pediatr Surg 2004; 39: 184-189. discussion 84-9.
27. Gitto E, Reiter RJ, Sabatino G, Buonocore G, Romeo C, Gitto P, Bugge C, Trimarchi G, Barberi I. Correlation among cytokines, bronchopulmonary dysplasia and modality of ventilation in preterm newborns: improvement with melatonin treatment. J Pineal Res 2005; 39: 287-293.
28. Gitto E, Reiter RJ, Karbownik M, Xian-Tan D, Barberi I. Respiratory distress syndrome in the newborn: role of oxidative stress. Intensive Care Med 2001; 27: 1116-1123.
29. Gitto E, Reiter RJ, Cordaro SP, La Rosa M, Chiurazzi P, Trimarchi G, Gitto P, Calabro MP, Barberi I. Oxidative and inflammatory parameters in respiratory distress syndrome of preterm newborns: beneficial effects of melatonin. Am J Perinatol 2004; 21: 209-216.
30. Gitto E, Reiter RJ, Amodio A, Romeo C, Cuzzocrea E, Sabatino G, Buonocore G, Cordaro V, Trimarchi G, Barberi I. Early indicators of chronic lung disease in preterm infants with respiratory distress syndrome and their inhibition by melatonin. J Pineal Res 2004; 36: 250-255.
31. Gitto E, Pellegrino S, Gitto P, Barberi I, Reiter RJ. Oxidative stress of the newborn in the pre- and post-natal period and the clinical utility of melatonin. J Pineal Res 2009; 46: 128-139.
32. Gitto E, Karbownik M, Reiter RJ, Tan DX, Cuzzocrea S, Chiurazzi P, Cordaro S, Corona G, Trimarchi G, Barberi I. Effects of melatonin treatment in septic newborns. Pediatr Res 2001; 50: 756-760.
33. Fulia F, Gitto E, Cuzzocrea S, Reiter RJ, Dugo L, Gitto P, Barberi S, Cordaro S, Barberi I. Increased levels of malondialdehyde and nitrite/nitrate in the blood of asphyxiated newborns: reduction by melatonin. J Pineal Res 2001; 31: 343-349.
34. Arendt J. Mammalian pineal rhythms. Pineal Res Rev 1985; 3: 161-213.
35. Arendt J. Melatonin. Clin Endocrinol (Oxf) 1988; 29: 205-229.
36. Vaughan GM. Melatonin in humans. In: Pineal Research Reviews, ed. Reiter RJ. New York: Liss, 1984; 141-201.
37. Fourtillan JB, Brisson AM, Fourtillan M, Ingrand I, Decourt JP, Girault J. Melatonin secretion occurs at a constant rate in both young and older men and women. Am J Physiol Endocrinol Metab 2001; 280: E11-22.
38. Lang U, Kornemark M, Aubert ML, Paunier L, Sizonenko PC. Radioimmunological determination of urinary melatonin in humans: correlation with plasma levels and typical 24-hour rhythmicity. J Clin Endocrinol Metab 1981; 53: 645-650.
39. Kovacs J, Brodner W, Kirchlechner V, Arif T, Waldhauser F. Measurement of urinary melatonin: a useful tool for monitoring serum melatonin after its oral administration. J Clin Endocrinol Metab 2000; 85: 666-670.
40. Ma X, Idle JR, Krausz KW, Gonzalez FJ. Metabolism of melatonin by human cytochromes p450. Drug Metab Dispos 2005; 33: 489-494.
41. CDC. U.S. Genome Variation Estimates. CYP1B1 Allele and Genotype Frequencies. Available polymorphism(s). In, edOffice of Surveillance E, and Laboratory Services [online]. Available at http://www.cdc.gov/genomics/population/genvar/frequencies/CYP1B1.htm (last accessed 30 November 2009).
42. Smits A, Allegaert K. Perinatal pharmacology: applications for neonatal neurology. Eur J Paediatr Neurol 2011; 15: 478-486.
43. Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, Solimano A, Tin W. Long-term effects of caffeine therapy for apnea of prematurity. N Engl J Med 2007; 357: 1893-1902.
44. Lane EA, Moss HB. Pharmacokinetics of melatonin in man: first pass hepatic metabolism. J Clin Endocrinol Metab 1985; 61: 1214-1216.
45. European Commission. Ethical considerations for clinical trials on medicinal products conducted with the paediatric population. Recommendations of the ad hoc group for the development of implementing guidelines for Directive 2001/20/EC relating to good clinical practice in the conduct of clinical trials on medicinal products for human use. In: EU Legislation - Eudralex, 2008. Available at http://ec.europa.eu/health/files/eudralex/vol-10/ethical_considerations_en.pdf (last accessed 4 April 2013).
46. Illnerova H, Buresova M, Presl J. Melatonin rhythm in human milk. J Clin Endocrinol Metab 1993; 77: 838-841.
47. Waldhauser F, Waldhauser M, Lieberman HR, Deng MH, Lynch HJ, Wurtman RJ. Bioavailability of oral melatonin in humans. Neuroendocrinology 1984; 39: 307-313.
48. Aldhous M, Franey C, Wright J, Arendt J. Plasma concentrations of melatonin in man following oral absorption of different preparations. Br J Clin Pharmacol 1985; 19: 517-521.